Equities

eFFECTOR Therapeutics Inc

eFFECTOR Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.31
  • Today's Change-0.07 / -5.07%
  • Shares traded87.46k
  • 1 Year change-95.94%
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

  • Revenue in USD (TTM)0.00
  • Net income in USD-34.63m
  • Incorporated2020
  • Employees14.00
  • Location
    eFFECTOR Therapeutics Inc142 North Cedros AvenueSuite B, Suite ASOLANA BEACH 92075United StatesUSA
  • Phone+1 (858) 925-8215
  • Fax+1 (302) 655-5049
  • Websitehttps://effector.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Silo Pharma Inc72.12k-3.53m6.31m3.00--1.20--87.46-1.18-1.200.0241.870.008----24,040.00-39.26-24.90-43.11-26.3991.9082.79-4,889.57-2,757.85----0.00--0.00--7.07------
TFF Pharmaceuticals Inc885.71k-19.93m6.32m19.00--0.9689--7.14-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
Reliv International Inc35.13m-175.48k6.35m208.00--0.916515.880.1808-0.1005-0.100520.126.552.098.02228.49---1.05-4.65-1.47-6.0640.9041.98-0.4996-2.331.07--0.1064---2.94-9.3776.65---35.85--
Galera Therapeutics Inc0.00-45.75m6.52m7.00---------0.9971-0.99710.00-2.480.00----0.00-115.30-83.69-142.79-97.54-----------6.499.23------5.05---29.84--
Kazia Therapeutics Ltd (ADR)14.99k-13.60m6.60m12.00--0.7126--440.04-0.8247-0.82470.00080.35110.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Longeveron Inc978.00k-21.62m6.60m23.00--0.8612--6.75-9.58-9.580.42971.210.0621--7.1442,521.74-132.19-63.15-184.16-75.6848.4733.70-2,129.24-441.02----0.00---41.98-19.78-17.92--26.80--
Hepion Pharmaceuticals Inc0.00-38.52m6.68m22.00--1.15-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
eFFECTOR Therapeutics Inc0.00-34.63m6.68m14.00--6.70-----13.31-13.310.000.21190.00----0.00-141.18-----------------17.120.9581---100.00---58.00------
4Cable TV International Inc758.68k-3.14m6.78m0.00------8.93-0.0624-0.06240.0157-0.04121.071.8425.22---441.73-82.30---308.1029.92---414.41-47.620.0064-0.5271-----0.0914---731.54------
Tenax Therapeutics Inc0.00-10.10m6.80m5.00--0.5467-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Actavia Life Sciences Inc0.00-406.65k6.95m1.00---------0.0005-0.00050.00-0.00280.00----0.00-805.97-158.17---------------5.63---------547.04------
22nd Century Group Inc29.75m-62.89m6.97m64.00------0.2342-40.02-97.9317.94-3.230.405.905.47464,796.90-66.29-46.78-92.49-54.18-33.09-2.11-165.75-107.950.4284-3.674.76---20.494.03-76.94--53.60--
Intelligent Bio Solutions Inc2.83m-10.03m7.04m17.00--0.5915--2.49-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Pulmatrix Inc11.68m-8.85m7.05m22.00--0.3706--0.6033-2.42-2.423.205.210.3517--17.84531,090.90-26.63-46.91-30.21-58.12-----75.73-238.04----0.00--20.21116.6225.03--104.29--
Data as of Jun 07 2024. Currency figures normalised to eFFECTOR Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

20.13%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 2024223.00k6.05%
StemPoint Capital LPas of 31 Mar 2024132.79k3.60%
Sectoral Asset Management, Inc.as of 31 Mar 202495.31k2.59%
The Vanguard Group, Inc.as of 31 Mar 202492.47k2.51%
Parallel Advisors LLCas of 31 Mar 202467.74k1.84%
Blackstone Alternative Investment Advisors LLCas of 31 Mar 202452.34k1.42%
Ensign Peak Advisors, Inc.as of 31 Mar 202432.95k0.89%
Geode Capital Management LLCas of 31 Mar 202422.61k0.61%
Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 202412.35k0.34%
Sea Otter Advisors LLCas of 31 Mar 202410.56k0.29%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.